Gene expression probe sets associated with outcome (EFS) in patients with MLL-AFF1
Rank . | Probe set . | Gene symbol . | Elevated in* . | SAM analysis . | Cox regression . | P (adjusted for age)‡ . | ||
---|---|---|---|---|---|---|---|---|
Score . | FDR (%) . | HR . | P† . | |||||
1 | 229461_x_at | NEGR1 | Low risk | −2.35 | 12.25 | 0.54 | .005 | .015 |
2 | 226415_at | VAT1L | Low risk | −2.19 | 12.25 | 0.59 | .007 | .014 |
1 | 228462_at | IRX2 | High risk | 2.08 | 10.93 | 1.53 | .010 | .010 |
2 | 230472_at | IRX1 | High risk | 1.99 | 10.93 | 1.51 | .023 | .060 |
3 | 202609_at | EPS8 | High risk | 1.99 | 10.93 | 1.52 | .006 | .036 |
4 | 201688_s_at | TPD52 | High risk | 1.97 | 10.93 | 1.63 | .008 | .012 |
5 | 214156_at | MYRIP | High risk | 1.92 | 10.93 | 1.64 | .005 | .055 |
6 | 209480_at | HLA-DQB1 | High risk | 1.89 | 10.93 | 1.49 | .023 | .006 |
7 | 205403_at | IL1R2 | High risk | 1.84 | 10.93 | 1.54 | .015 | .153 |
8 | 212192_at | KCTD12 | High risk | 1.83 | 10.93 | 1.56 | .021 | .059 |
9 | 201743_at | CD14 | High risk | 1.73 | 10.93 | 1.50 | .017 | .121 |
10 | 1555745_a_at | LYZ | High risk | 1.73 | 10.93 | 1.53 | .031 | .059 |
11 | 203535_at | S100A9 | High risk | 1.70 | 10.93 | 1.51 | .030 | .091 |
12 | 238900_at | HLA-DRB1… | High risk | 1.70 | 10.93 | 1.48 | .018 | .031 |
13 | 201689_s_at | TPD52 | High risk | 1.67 | 10.93 | 1.49 | .029 | .027 |
14 | 204959_at | MNDA | High risk | 1.65 | 10.93 | 1.51 | .032 | .202 |
15 | 211372_s_at | IL1R2 | High risk | 1.64 | 10.93 | 1.65 | .008 | .156 |
16 | 218454_at | PLBD1 | High risk | 1.61 | 10.93 | 1.55 | .015 | .159 |
17 | 211571_s_at | VCAN | High risk | 1.59 | 10.93 | 1.44 | .046 | .192 |
18 | 202289_s_at | TACC2 | High risk | 1.56 | 10.93 | 1.45 | .039 | .055 |
19 | 228434_at | BTNL9 | High risk | 1.56 | 10.93 | 1.58 | .021 | .064 |
20 | 202917_s_at | S100A8 | High risk | 1.55 | 10.93 | 1.48 | .054 | .098 |
21 | 204620_s_at | VCAN | High risk | 1.54 | 10.93 | 1.43 | .058 | .210 |
22 | 205863_at | S100A12 | High risk | 1.52 | 10.93 | 1.43 | .043 | .145 |
23 | 201690_s_at | TPD52 | High risk | 1.50 | 10.93 | 1.49 | .047 | .039 |
24 | 204619_s_at | VCAN | High risk | 1.48 | 10.93 | 1.40 | .058 | .194 |
25 | 215646_s_at | VCAN | High risk | 1.45 | 10.93 | 1.39 | .070 | .217 |
26 | 221731_x_at | VCAN | High risk | 1.45 | 10.93 | 1.41 | .076 | .238 |
27 | 204971_at | CSTA | High risk | 1.40 | 12.25 | 1.44 | .071 | .260 |
Rank . | Probe set . | Gene symbol . | Elevated in* . | SAM analysis . | Cox regression . | P (adjusted for age)‡ . | ||
---|---|---|---|---|---|---|---|---|
Score . | FDR (%) . | HR . | P† . | |||||
1 | 229461_x_at | NEGR1 | Low risk | −2.35 | 12.25 | 0.54 | .005 | .015 |
2 | 226415_at | VAT1L | Low risk | −2.19 | 12.25 | 0.59 | .007 | .014 |
1 | 228462_at | IRX2 | High risk | 2.08 | 10.93 | 1.53 | .010 | .010 |
2 | 230472_at | IRX1 | High risk | 1.99 | 10.93 | 1.51 | .023 | .060 |
3 | 202609_at | EPS8 | High risk | 1.99 | 10.93 | 1.52 | .006 | .036 |
4 | 201688_s_at | TPD52 | High risk | 1.97 | 10.93 | 1.63 | .008 | .012 |
5 | 214156_at | MYRIP | High risk | 1.92 | 10.93 | 1.64 | .005 | .055 |
6 | 209480_at | HLA-DQB1 | High risk | 1.89 | 10.93 | 1.49 | .023 | .006 |
7 | 205403_at | IL1R2 | High risk | 1.84 | 10.93 | 1.54 | .015 | .153 |
8 | 212192_at | KCTD12 | High risk | 1.83 | 10.93 | 1.56 | .021 | .059 |
9 | 201743_at | CD14 | High risk | 1.73 | 10.93 | 1.50 | .017 | .121 |
10 | 1555745_a_at | LYZ | High risk | 1.73 | 10.93 | 1.53 | .031 | .059 |
11 | 203535_at | S100A9 | High risk | 1.70 | 10.93 | 1.51 | .030 | .091 |
12 | 238900_at | HLA-DRB1… | High risk | 1.70 | 10.93 | 1.48 | .018 | .031 |
13 | 201689_s_at | TPD52 | High risk | 1.67 | 10.93 | 1.49 | .029 | .027 |
14 | 204959_at | MNDA | High risk | 1.65 | 10.93 | 1.51 | .032 | .202 |
15 | 211372_s_at | IL1R2 | High risk | 1.64 | 10.93 | 1.65 | .008 | .156 |
16 | 218454_at | PLBD1 | High risk | 1.61 | 10.93 | 1.55 | .015 | .159 |
17 | 211571_s_at | VCAN | High risk | 1.59 | 10.93 | 1.44 | .046 | .192 |
18 | 202289_s_at | TACC2 | High risk | 1.56 | 10.93 | 1.45 | .039 | .055 |
19 | 228434_at | BTNL9 | High risk | 1.56 | 10.93 | 1.58 | .021 | .064 |
20 | 202917_s_at | S100A8 | High risk | 1.55 | 10.93 | 1.48 | .054 | .098 |
21 | 204620_s_at | VCAN | High risk | 1.54 | 10.93 | 1.43 | .058 | .210 |
22 | 205863_at | S100A12 | High risk | 1.52 | 10.93 | 1.43 | .043 | .145 |
23 | 201690_s_at | TPD52 | High risk | 1.50 | 10.93 | 1.49 | .047 | .039 |
24 | 204619_s_at | VCAN | High risk | 1.48 | 10.93 | 1.40 | .058 | .194 |
25 | 215646_s_at | VCAN | High risk | 1.45 | 10.93 | 1.39 | .070 | .217 |
26 | 221731_x_at | VCAN | High risk | 1.45 | 10.93 | 1.41 | .076 | .238 |
27 | 204971_at | CSTA | High risk | 1.40 | 12.25 | 1.44 | .071 | .260 |
Bold denotes probe sets that are used for building the 7-gene (9-probe set) SPCA model.
Indicates risk group with which elevated expression is correlated.
P value of Wald test for the HR indicating significance of the association between the expression of each individual gene and treatment outcome.
P value indicating significance of the association between the expression of each gene and treatment outcome adjusting for age effect.